Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated September 19, 2016, reports on the positive topline results of the Phase III EXPAND study for BAF312 (siponimod). The study focuses on the treatment of secondary progressive multiple sclerosis (SPMS), a progressive and highly disabling form of the disease with significant unmet medical needs. The data was presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics for the reporting period. The text references historical 2015 data in the "About Novartis" section, noting net sales of USD 49.4 billion and R&D spending of approximately USD 8.9 billion, but these are not part of the current period's financial reporting.
Material Changes and Clinical Results
The primary material update is the successful outcome of the EXPAND study, the largest randomized, controlled study in SPMS to date, involving 1,651 patients from 31 countries. Key clinical findings include:
- Disability Progression: Treatment with BAF312 reduced the risk of three-month confirmed disability progression by 21% compared with placebo (p=0.013). The risk reduction for six-month confirmed disability progression was greater.
- Consistency: A consistent reduction in risk was observed across predefined subgroups, including patients without relapses.
- Secondary Endpoints: Significant differences in favor of BAF312 were observed in annualized relapse rate, percent change in brain volume, and change from baseline in T2 lesion volume. The difference in the Timed 25-Foot Walk test (T25FW) was not significant.
- Safety: BAF312 was generally safe and well tolerated, with a profile comparable to other drugs in the same class.
Guidance, Outlook, and Risks
Management commentary indicates that Novartis will complete full analyses of the EXPAND data and evaluate next steps in consultation with health authorities. The company views these results as a positive stride forward in an unserved disease area. The filing includes a standard disclaimer regarding forward-looking statements, noting that there can be no guarantee that BAF312 will be approved for sale in any market or at any particular time. Risks include uncertainties inherent in research and development, unexpected clinical trial results, regulatory delays, and the ability to obtain proprietary intellectual property protection.
Investor Verification Checklist
- Verify the timeline for regulatory submission and potential approval of BAF312 (siponimod) for SPMS.
- Monitor the publication of full study results, including data from primary and secondary endpoints.
- Assess the potential commercial impact of BAF312 on Novartis's MS portfolio, which currently includes Gilenya and Extavia.
- Review the safety profile of BAF312 in long-term follow-up data compared to existing S1P modulators.
- Confirm the status of other investigational compounds mentioned, such as ofatumumab (OMB157) for relapsing MS.